Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
Powered By

FDA OKs New Biologic Option for PsA

Written by Ted Samson
Posted on November 18, 2026

The U.S. Food and Drug Administration (FDA) has approved the biologic Ilumya (tildrakizumab-asmn) for adults with active psoriatic arthritis (PsA). This medication was already approved for adults with moderate to severe plaque psoriasis.

In two clinical trials, 35 percent to 41 percent of people receiving Ilumya had at least a 20 percent improvement in arthritis activity after 24 weeks. This outcome was compared with 23 percent to 25 percent of those receiving a placebo (inactive treatment).

The new approval gives people living with PsA another treatment option to discuss with their healthcare team.

🗳️ Have you tried a biologic medication for psoriatic arthritis?
Yes, and it helped
Yes, but it didn’t help
No, but I am interested
No, and I am not interested

What Is Ilumya?

Ilumya is a formulation of tildrakizumab-asmn, a biologic medication that targets interleukin-23 (IL-23). IL-23 is a protein involved in the body’s immune response and inflammation. Ilumya works by blocking IL-23, helping reduce inflammation.

Ilumya is given as a subcutaneous (under-the-skin) injection by a healthcare provider. The dosing schedule depends on whether a person also has moderate-to-severe plaque psoriasis.

What Did Clinical Trials Show?

The FDA approval was based on two separate phase 3 clinical trials, called PsA2 and PsA3, involving 806 adults with active PsA. Participants received tildrakizumab or a placebo for 24 weeks. Some continued taking other arthritis medications during the studies.

Researchers measured how many participants achieved an American College of Rheumatology 20 (ACR20) response. This means they showed at least a 20 percent improvement in measures of arthritis activity, including tender and swollen joints.

At week 24, researchers found:

PsA2 trial — 41 percent of people receiving tildrakizumab achieved an ACR20 response, compared with 25 percent receiving placebo. This was a difference of 16 percentage points based on the rounded percentages.
PsA3 trial — 35 percent of people receiving tildrakizumab achieved an ACR20 response, compared with 23 percent receiving placebo. This was a difference of 12 percentage points based on the rounded percentages.

The results suggest that Ilumya can help reduce arthritis activity for some adults. But not everyone responded to treatment, and the trials didn’t directly compare tildrakizumab with other biologics.

What Are the Possible Side Effects?

Like other medications that affect the immune system, Ilumya has potential risks.

In the PsA clinical trials, the most commonly reported adverse reactions occurring in at least 3 percent of people taking Ilumya and more often than with placebo were:

Upper respiratory tract infections, such as infections affecting the nose or throat
COVID-19

Ilumya may increase the risk of infections. Before starting treatment, your healthcare provider should check you for tuberculosis and discuss potential side effects with you.

What Does This Approval Mean for People With Psoriatic Arthritis?

Having another FDA-approved treatment option may be helpful for people whose PsA symptoms aren’t well controlled or who are exploring different approaches with their rheumatologist.

Ilumya’s dosing schedule may also be an important consideration. The medication is given by a healthcare provider rather than self-injected at home. Maintenance doses are typically scheduled every 12 weeks.

If you’re living with PsA and aren’t satisfied with your current treatment, you may want to explore other options. Talk with your rheumatologist about which treatments might best fit your symptoms, needs, and goals.

Share this article
All updates must be accompanied by text or a picture.

We'd love to hear from you! Please share your name and email to post and read comments.

You'll also get the latest articles directly to your inbox.

Subscriber Photo Subscriber Photo Subscriber Photo
250,182 members
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy • Terms of Use
All updates must be accompanied by text or a picture.

Subscribe now to ask your question, get answers, and stay up to date on the latest articles.

Get updates directly to your inbox.

Subscriber Photo Subscriber Photo Subscriber Photo
250,182 members
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy • Terms of Use
Continue with Facebook
Continue with Google
By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.
Already a member? Log In

Thank you for subscribing!

Become a member to get even more

See answer